CD86 and neoplasm: In addition, the rates of matured DCs (CD11c+CD86+CD80+) and cytotoxic T cells (CD3+CD8+) in lymph nodes after DiD@HMV treatment were also elevated (Supplementary Fig. 53g, h), indicating that the HMVs could act as autologous tumor-cell vaccines for cancer immunotherapy.